| Similar Articles |
|---|
 |
The Motley Fool
October 18, 2007
Brian Lawler |
Genzyme Shows Off a Drug Candidate A top compound in development could become an important MS treatment.   |
The Motley Fool
January 9, 2008
Brian Orelli |
Genzyme Buys Into Antisense RNA -- Big Time Genzyme buys a piece of Isis' mipomersen at a wowser of a price. |
The Motley Fool
August 5, 2010
Brian Orelli |
Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still. |
The Motley Fool
May 20, 2009
Brian Orelli |
Clinical Trial Positive, Stock Not So Much Isis and Genzyme hit a homer with their cholesterol drug, mipomersen, but they'll need another big play to win the game. |
The Motley Fool
April 28, 2008
Brian Orelli |
FDA Moves Isis' Finish Line The FDA tells drugmaker Isis it must complete cancer tests before submitting its marketing application. |
The Motley Fool
October 12, 2006
Brian Lawler |
Genzyme Runs a Tight Ship Revenues are up at the biopharmaceutical company, but shares dropped in morning trading. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects. |
The Motley Fool
October 29, 2007
Brian Lawler |
Genzyme Gets It Together Genzyme may not engender as much investor excitement as Carl-Icahn-acquisition-hyped biopharmas. But its diverse pipeline, and the strong performance it delivers quarter after quarter, deserve some investor attention. |
The Motley Fool
November 18, 2009
Brian Orelli |
Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data. |
The Motley Fool
January 11, 2011
Brian Orelli |
A Clear Drug-Development Path -- Times 2 The FDA throws a fork in the road for Isis and Genzyme. |
The Motley Fool
April 9, 2008
Brian Orelli |
Isis Ignited by Bristol-Myers Bristol-Myers Squibb selects an Isis-developed compound, triggering a milestone payment. |
The Motley Fool
May 17, 2011
Brian Orelli |
$3 Million Here, $1.5 Billion There Isis makes progress in its pact with GlaxoSmithKline. |
The Motley Fool
April 8, 2010
Brian Orelli |
Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult. |
The Motley Fool
March 31, 2010
Brian Orelli |
A Double-Digit Jump? For That? Isis' drug discovery license doesn't look too exciting to me. |
The Motley Fool
October 15, 2007
Brian Lawler |
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. |
The Motley Fool
May 15, 2007
Mike Havrilla |
Eyeing ISIS A robust pipeline and a promising cholesterol drug could benefit this pharmaceutical firm. Investors, take note. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
August 29, 2006
Brian Lawler |
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. |
The Motley Fool
September 24, 2010
Brian Orelli |
Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year. |
The Motley Fool
January 9, 2008
Brian Lawler |
Tracking Genzyme The biopharma updates investors on what to expect for 2008. |
Chemistry World
January 3, 2014
Ben Valsler |
Sanofi suffers multiple sclerosis setback French pharmaceutical Sanofi has run into trouble after the US Food and Drug Administration rejected its multiple sclerosis drug Lemtrada (alemtuzumab). |
The Motley Fool
July 18, 2005
Stephen D. Simpson |
Rare Diseases Mean Solid Growth for Genzyme Genzyme doesn't target well-known diseases, but then neither does the competition. Valuing these shares is a bit tricky. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
April 26, 2007
Brian Lawler |
Genzyme Is Good The biopharma giant announced unexpectedly strong first-quarter results on the back of higher sales of recently launched compounds. |
The Motley Fool
July 23, 2009
Brian Orelli |
This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme |
The Motley Fool
October 4, 2010
Ryan McBride |
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. |
The Motley Fool
June 23, 2010
Brian Orelli |
A Novel Drug Technology Worth Watching Regulus signs up another microRNA partner. |
The Motley Fool
February 8, 2005
Charly Travers |
Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance. |
The Motley Fool
March 2, 2004
David Nierengarten |
Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines. |
The Motley Fool
October 4, 2007
Billy Fisher |
Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
January 9, 2008
Brian Lawler |
Checking In on Biogen Biogen Idec presents at the JPMorgan Healthcare Conference, reiterating its long-term guidance of 15% compound annual sales growth and 20% average non-GAAP earnings-per-share growth from 2007 through 2010. |
The Motley Fool
December 4, 2008
Brian Orelli |
Poor Pozen It's not often that you see a drug developer release data from two positive phase 3 trials for its lead pipeline compound and see its shares fall more than 4%, but that's what happened to Pozen. |
The Motley Fool
September 14, 2006
Brian Lawler |
Close Failure for Genzyme Will Genzyme's Campath get approval? Investors shouldn't hold their breath. |
The Motley Fool
July 27, 2007
Brian Lawler |
Jumpstarting Genzyme A great quarter for Genzyme. All three of its top products had double-digit percentage sales gains; operating margins are up too. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Multiple Sclerosis: The Advent of the Orals The $8 billion dollar multiple sclerosis market is set to double the number of available treatments in the near future, with a dramatic switch from injectables to oral medications. |
Chemistry World
February 17, 2011
Sarah Houlton |
Sanofi to buy Genzyme in $20 billion deal Sanofi-Aventis has won its long-running battle for Genzyme, and is to acquire the US-based biotech for $74 ( 46) per share - about $20 billion in total - plus extra payments of up to $14 per share. |
Pharmaceutical Executive
November 1, 2008
Jim Wahl |
The Mess in MS A five-year forecast of the multiple-sclerosis market following the disruptions of Tysabri. |
The Motley Fool
February 18, 2005
John Bluis |
Genzyme's Acquisitions Pay Off With some of this biotech's major decisions coming to fruition, shareholders can have more confidence that management can deliver on its promises. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
May 25, 2005
Brian Gorman |
Another Deal for Isis Investors shouldn't get their hopes up over the drugmaker's latest collaboration. |
The Motley Fool
October 28, 2010
Brian Orelli |
This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37. |
The Motley Fool
April 20, 2006
John Bluis |
Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management. |
The Motley Fool
December 13, 2010
Brian Orelli |
Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price. |
The Motley Fool
February 12, 2009
Brian Orelli |
Cruising, but Ready to Take Off Genzyme's in wait-and-see mode. |
The Motley Fool
September 13, 2010
Brian Orelli |
When All Else Fails, Sell! Genzyme has no other choice. |
The Motley Fool
August 30, 2010
Ryan McBride |
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
